MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 318099 | Name: Levofloxacin
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Levofloxacin is an antibiotic. It is used to treat a number of bacterial infections including acute bacterial sinusitis, pneumonia, urinary tract infections, chronic prostatitis, and some types of gastroenteritis. Along with other antibiotics it may be used to treat tuberculosis, meningitis, or pelvic inflammatory disease. It is administered by mouth or intravenously.

Chemical Structure

Levofloxacin
CAS#100986-85-4

Theoretical Analysis

MedKoo Cat#: 318099

Name: Levofloxacin

CAS#: 100986-85-4

Chemical Formula: C18H20FN3O4

Exact Mass: 361.1438

Molecular Weight: 361.37

Elemental Analysis: C, 59.83; H, 5.58; F, 5.26; N, 11.63; O, 17.71

Price and Availability

Size Price Availability Quantity
5g USD 250.00 2 Weeks
25g USD 450.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
100986-85-4 138199-71-0 (Hemihydrate) 177325-13-2 (HCl)
Synonym
Levofloxacin, Levaquin, Tavanic, Iquix, Quixin
IUPAC/Chemical Name
(S)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid
InChi Key
GSDSWSVVBLHKDQ-JTQLQIEISA-N
InChi Code
InChI=1S/C18H20FN3O4/c1-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7-13(19)15(17)21-5-3-20(2)4-6-21/h7-8,10H,3-6,9H2,1-2H3,(H,24,25)/t10-/m0/s1
SMILES Code
O=C(C(C1=O)=CN2[C@@H](C)COC3=C(N4CCN(C)CC4)C(F)=CC1=C23)O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
Levofloxacin inhibits the DNA gyrase and topoisomerase IV.
In vitro activity:
Levofloxacin exhibited twofold greater inhibitory and bactericidal activities than ofloxacin against either extracellular or intracellular tubercle bacilli. Reference: Antimicrob Agents Chemother. 1994 May;38(5):1161-4. https://pubmed.ncbi.nlm.nih.gov/8067756/
In vivo activity:
This study investigated the toxic effect of levofloxacin (LVFX), a quinolone antibacterial agent, on cartilage by examining aspects of its in vivo toxicokinetics and effect on the function of cultured chondrocytes of the femoral articular cartilage from juvenile New Zealand White rabbits. Repeated administration of LVFX (100 mg/kg) orally for 7 days induced focal necrosis and superficial erosion in the articular cartilage of the femoral condyle, but 30 mg/kg did not. Reference: Antimicrob Agents Chemother. 1995 Sep;39(9):1979-83. https://pubmed.ncbi.nlm.nih.gov/8540702/
Solvent mg/mL mM comments
Solubility
DMSO 19.7 54.42
Ethanol 11.0 30.44
PBS (pH 7.2) 5.0 13.84
Water 8.0 22.14
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 361.37 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Mor N, Vanderkolk J, Heifets L. Inhibitory and bactericidal activities of levofloxacin against Mycobacterium tuberculosis in vitro and in human macrophages. Antimicrob Agents Chemother. 1994 May;38(5):1161-4. doi: 10.1128/AAC.38.5.1161. PMID: 8067756; PMCID: PMC188169. 2. Fu KP, Lafredo SC, Foleno B, Isaacson DM, Barrett JF, Tobia AJ, Rosenthale ME. In vitro and in vivo antibacterial activities of levofloxacin (l-ofloxacin), an optically active ofloxacin. Antimicrob Agents Chemother. 1992 Apr;36(4):860-6. doi: 10.1128/AAC.36.4.860. Erratum in: Antimicrob Agents Chemother 1992 Aug;36(8):1797. PMID: 1503449; PMCID: PMC189464. 3. Kato M, Takada S, Ogawara S, Takayama S. Effect of levofloxacin on glycosaminoglycan and DNA synthesis of cultured rabbit chondrocytes at concentrations inducing cartilage lesions in vivo. Antimicrob Agents Chemother. 1995 Sep;39(9):1979-83. doi: 10.1128/AAC.39.9.1979. PMID: 8540702; PMCID: PMC162867. 4. JI B, Lounis N, Truffot-Pernot C, Grosset J. In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother. 1995 Jun;39(6):1341-4. doi: 10.1128/AAC.39.6.1341. PMID: 7574527; PMCID: PMC162738.
In vitro protocol:
1. Mor N, Vanderkolk J, Heifets L. Inhibitory and bactericidal activities of levofloxacin against Mycobacterium tuberculosis in vitro and in human macrophages. Antimicrob Agents Chemother. 1994 May;38(5):1161-4. doi: 10.1128/AAC.38.5.1161. PMID: 8067756; PMCID: PMC188169. 2. Fu KP, Lafredo SC, Foleno B, Isaacson DM, Barrett JF, Tobia AJ, Rosenthale ME. In vitro and in vivo antibacterial activities of levofloxacin (l-ofloxacin), an optically active ofloxacin. Antimicrob Agents Chemother. 1992 Apr;36(4):860-6. doi: 10.1128/AAC.36.4.860. Erratum in: Antimicrob Agents Chemother 1992 Aug;36(8):1797. PMID: 1503449; PMCID: PMC189464.
In vivo protocol:
1. Kato M, Takada S, Ogawara S, Takayama S. Effect of levofloxacin on glycosaminoglycan and DNA synthesis of cultured rabbit chondrocytes at concentrations inducing cartilage lesions in vivo. Antimicrob Agents Chemother. 1995 Sep;39(9):1979-83. doi: 10.1128/AAC.39.9.1979. PMID: 8540702; PMCID: PMC162867. 2. JI B, Lounis N, Truffot-Pernot C, Grosset J. In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother. 1995 Jun;39(6):1341-4. doi: 10.1128/AAC.39.6.1341. PMID: 7574527; PMCID: PMC162738.
1: Charfi O, Lakhoua G, Sahnoun R, Badri T, Daghfous R, El Aidli S, Kastalli S, Zaïem A. DRESS Syndrome Following Levofloxacin Exposure With Positive Patch-test. Therapie. 2015 Nov-Dec;70(6):547-9. doi: 10.2515/therapie/2015046. Epub 2015 Aug 3. Review. PubMed PMID: 26238129. 2: Lu ZK, Yuan J, Li M, Sutton SS, Rao GA, Jacob S, Bennett CL. Cardiac risks associated with antibiotics: azithromycin and levofloxacin. Expert Opin Drug Saf. 2015 Feb;14(2):295-303. doi: 10.1517/14740338.2015.989210. Epub 2014 Dec 10. Review. PubMed PMID: 25494485; PubMed Central PMCID: PMC4404501. 3: Stockmann C, Hillyard B, Ampofo K, Spigarelli MG, Sherwin CM. Levofloxacin inhalation solution for the treatment of chronic Pseudomonas aeruginosa infection among patients with cystic fibrosis. Expert Rev Respir Med. 2015 Feb;9(1):13-22. doi: 10.1586/17476348.2015.986469. Epub 2014 Nov 24. Review. PubMed PMID: 25417708. 4: Lazicka-Gałecka M, Gałecki T, Szaflik JP. [A review of safety and efficacy of levofloxacin 0.5% ophthalmic solution in the treatment of external ocular infections and in prophylaxis of postoperative endophthalmitis]. Klin Oczna. 2015;117(2):123-9. Review. Polish. PubMed PMID: 26638552. 5: Levine C, Trivedi A, Thung SN, Perumalswami PV. Severe ductopenia and cholestasis from levofloxacin drug-induced liver injury: a case report and review. Semin Liver Dis. 2014 May;34(2):246-51. doi: 10.1055/s-0034-1375964. Epub 2014 May 31. Review. PubMed PMID: 24879988. 6: Ye CL, Liao GP, He S, Pan YN, Kang YB, Zhang ZY. Levofloxacin and proton pump inhibitor-based triple therapy versus standard triple first-line therapy for Helicobacter pylori eradication. Pharmacoepidemiol Drug Saf. 2014 May;23(5):443-55. doi: 10.1002/pds.3581. Epub 2014 Feb 21. Review. PubMed PMID: 24677603. 7: Xiao SP, Gu M, Zhang GX. Is levofloxacin-based triple therapy an alternative for first-line eradication of Helicobacter pylori? A systematic review and meta-analysis. Scand J Gastroenterol. 2014 May;49(5):528-38. doi: 10.3109/00365521.2014.887765. Epub 2014 Mar 11. Review. PubMed PMID: 24611790. 8: Stockmann C, Sherwin CM, Ampofo K, Spigarelli MG. Development of levofloxacin inhalation solution to treat Pseudomonas aeruginosa in patients with cystic fibrosis. Ther Adv Respir Dis. 2014 Feb;8(1):13-21. doi: 10.1177/1753465813508445. Epub 2013 Dec 10. Review. PubMed PMID: 24334337. 9: Gao CH, Yu LS, Zeng S, Huang YW, Zhou Q. Personalized therapeutics for levofloxacin: a focus on pharmacokinetic concerns. Ther Clin Risk Manag. 2014 Mar 27;10:217-27. doi: 10.2147/TCRM.S59079. eCollection 2014. Review. PubMed PMID: 24707182; PubMed Central PMCID: PMC3972025. 10: Rafat C, Debrix I, Hertig A. Levofloxacin for the treatment of pyelonephritis. Expert Opin Pharmacother. 2013 Jun;14(9):1241-53. doi: 10.1517/14656566.2013.792805. Epub 2013 Apr 24. Review. PubMed PMID: 23614756. 11: Di Caro S, Fini L, Daoud Y, Grizzi F, Gasbarrini A, De Lorenzo A, Di Renzo L, McCartney S, Bloom S. Levofloxacin/amoxicillin-based schemes vs quadruple therapy for Helicobacter pylori eradication in second-line. World J Gastroenterol. 2012 Oct 28;18(40):5669-78. doi: 10.3748/wjg.v18.i40.5669. Review. PubMed PMID: 23155306; PubMed Central PMCID: PMC3484334. 12: Parra-Riffo H, Lemus-Peñaloza J. Severe levofloxacin-induced hypoglycaemia: a case report and literature review. Nefrologia. 2012 Jul 17;32(4):546-7. doi: 10.3265/Nefrologia.pre2012.Feb.11248. Review. English, Spanish. PubMed PMID: 22806298. 13: Torres A, Liapikou A. Levofloxacin for the treatment of respiratory tract infections. Expert Opin Pharmacother. 2012 Jun;13(8):1203-12. doi: 10.1517/14656566.2012.688952. Review. PubMed PMID: 22594848. 14: Levofloxacin revisited. Med Lett Drugs Ther. 2011 Jul 11;53(1368):55. Review. PubMed PMID: 21738109. 15: Wernicke AG, Swistel AJ, Parashar B, Myskowski PL. Levofloxacin-induced radiation recall dermatitis: a case report and a review of the literature. Clin Breast Cancer. 2010 Oct 1;10(5):404-6. doi: 10.3816/CBC.2010.n.054. Review. PubMed PMID: 20920986. 16: Noreddin AM, Elkhatib WF. Levofloxacin in the treatment of community-acquired pneumonia. Expert Rev Anti Infect Ther. 2010 May;8(5):505-14. doi: 10.1586/eri.10.35. Review. PubMed PMID: 20455679. 17: Liu HH. Safety profile of the fluoroquinolones: focus on levofloxacin. Drug Saf. 2010 May 1;33(5):353-69. doi: 10.2165/11536360-000000000-00000. Review. PubMed PMID: 20397737. 18: Mirone V. [From cystitis to bacterial prostatitis: experience with levofloxacin]. Infez Med. 2009 Dec;17 Suppl 5:29-35. Review. Italian. PubMed PMID: 20424534. 19: Pea F. [PK/PD profile and post-marketing surveillance of levofloxacin]. Infez Med. 2009 Dec;17 Suppl 5:13-22. Review. Italian. PubMed PMID: 20424532. 20: Blasi F. [Therapeutic experience with levofloxacin in pneumonia and COPD]. Infez Med. 2009 Dec;17 Suppl 5:23-8. Review. Italian. PubMed PMID: 20424533.